FIG. 1.

Mice lacking the transcription factor Nrf2 show a more severe response to EAE. (A) Clinical scores of disease as described in the Materials and Methods were monitored daily after injection of 100 μg of MOG-35-55 emulsified in CFA. (B) Percent incidence of the severity of disease was documented as follows—0, no clinical score; 0.5–1.5, mild EAE; and 2.0 or above, severe EAE. (C) Onset of EAE was tracked, and the percent of total numbers of mice responding to immunization with MOG 35-55 is represented for WT and Nrf2-KO mice. Onset curves are significantly different, p < 0.003 (χ² = 8.853). Data in (A) are presented as mean ± SEM. *Significantly different than WT control (p < 0.05).